These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Description and analysis of clinical pathways for oesophago-gastric adenocarcinoma, in 10 European countries (the EURECCA upper gastro intestinal group - European Registration of Cancer Care). Messager M; de Steur W; Boelens PG; Jensen LS; Mariette C; Reynolds JV; Osorio J; Pera M; Johansson J; Kołodziejczyk P; Roviello F; De Manzoni G; Mönig SP; Allum WH; Eur J Surg Oncol; 2016 Sep; 42(9):1432-47. PubMed ID: 26898839 [TBL] [Abstract][Full Text] [Related]
3. The Current Status of Immunotherapies in Esophagogastric Cancer. Ku GY Surg Oncol Clin N Am; 2017 Apr; 26(2):277-292. PubMed ID: 28279469 [TBL] [Abstract][Full Text] [Related]
4. What's New in Gastric and Esophageal Cancers. Tanabe K Ann Surg Oncol; 2016 Nov; 23(12):3773. PubMed ID: 27638669 [No Abstract] [Full Text] [Related]
5. Variations among 5 European countries for curative treatment of resectable oesophageal and gastric cancer: A survey from the EURECCA Upper GI Group (EUropean REgistration of Cancer CAre). Messager M; de Steur WO; van Sandick JW; Reynolds J; Pera M; Mariette C; Hardwick RH; Bastiaannet E; Boelens PG; van deVelde CJ; Allum WH; Eur J Surg Oncol; 2016 Jan; 42(1):116-22. PubMed ID: 26461256 [TBL] [Abstract][Full Text] [Related]
10. Common data items in seven European oesophagogastric cancer surgery registries: towards a European upper GI cancer audit (EURECCA Upper GI). de Steur WO; Henneman D; Allum WH; Dikken JL; van Sandick JW; Reynolds J; Mariette C; Jensen L; Johansson J; Kolodziejczyk P; Hardwick RH; van de Velde CJ; Eur J Surg Oncol; 2014 Mar; 40(3):325-9. PubMed ID: 24412054 [TBL] [Abstract][Full Text] [Related]
11. Three decades of oesophagogastric cancer care: now a curable disease. Phillips AW; Griffin SM Br J Surg; 2021 Jun; 108(6):595-597. PubMed ID: 33748863 [No Abstract] [Full Text] [Related]
12. Early diagnosis and management of esophageal and gastric cancer. Lang GD; Konda VJ Minerva Gastroenterol Dietol; 2013 Dec; 59(4):357-76. PubMed ID: 24212354 [TBL] [Abstract][Full Text] [Related]
13. The "two-week wait" referral pathway allows prompt treatment but does not improve outcome for patients with oesophago-gastric cancer. Sharpe D; Williams RN; Ubhi SS; Sutton CD; Bowrey DJ Eur J Surg Oncol; 2010 Oct; 36(10):977-81. PubMed ID: 20702059 [TBL] [Abstract][Full Text] [Related]
14. Histopathologic classification of adenocarcinoma of the esophagogastric junction. Baldus SE Recent Results Cancer Res; 2010; 182():29-38. PubMed ID: 20676869 [No Abstract] [Full Text] [Related]
16. [Toward more understanding of esophagogastric cancer]. Xu JM Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):801-3. PubMed ID: 22335942 [No Abstract] [Full Text] [Related]
17. Curative management of adenocarcinoma of the oesophagus and oesogastric junction--current recommendations of the Belgian Working Group. Van Laethem JL; Baert F; Buset M; de Hemptine B; De Ronde T; Honoré P; Lerut T; Scaillet P; Van Cutsem E; Acta Gastroenterol Belg; 2000; 63(3):304-6. PubMed ID: 11189997 [No Abstract] [Full Text] [Related]